Immunosuppression and anti-inflammatory agents in ALS

Amyotrophic Lateral Sclerosis

Volumn 1, Issue 4, 2000, Pages 33-43

  Smith, R Glenn ^a   Appel, S H ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; PROSTAGLANDIN SYNTHASE;

AMYOTROPHIC LATERAL SCLEROSIS; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0347303313     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820050515692-1     Document Type: Article

References (122)

1. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707-719.
2. Smith RG, Appel SH. Molecular approaches to amyotrophic lateral sclerosis. Ann Rev Med 1995; 46: 133-145.
3. Smith RG, Siklos L, Alexianu ME, et al. Autoimmunity and ALS. Neurology 1996; 47: S40-45; discussion S45-46.
4. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 364: 362. (Pubitemid 23265284)
5. Engelhardt JI, Siklos L, Appel SH. Altered calcium home-ostasis and ultrastructure in motoneurons of mice caused by passively transferred anti-motoneuronal IgG. J Neuropathol Experi Neurol 1997; 56: 21-39. (Pubitemid 127470324)
6. Siklos L, Engelhardt J, Harati Y, Smith RG, Joo F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 1996; 39: 203-216. (Pubitemid 26071571)
7. Siklos L, Engelhardt JI, Alexianu ME, Gurney ME, Siddique T, Appel SH. Intracellular calcium parallels motoneuron degeneration in SOD-1 mutant mice. J Neuropathol Experi Neurol1998; 57: 571-587.
8. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20: 589-602. (Pubitemid 28153087)
9. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25. (Pubitemid 20222147)
10. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Eng J Med 1992; 326: 1464-1468.
11. Bowling AC, Schulz JB, Brown RH, Jr., Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. Journal of Neurochemistry 1993; 61: 2322-2325. (Pubitemid 23354097)
12. Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1998; 44: 696-699. (Pubitemid 28477861)
13. Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci USA 1996; 93: 5709-5714. (Pubitemid 26190744)
14. Kruman, II, Pedersen WA, Springer JE, Mattson MP. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeosta-sis. Experi Neurol 1999; 160: 28-39.
15. Liu D, Wen J, Liu J, Li L. The roles of free radicals in amy-otrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J 1999; 13: 2318-2328.
16. +: implications for neurodegeneration. J Neuro-chem1994; 63: 584-591.
17. Carriedo SG, Sensi SL, Yin HZ, Weiss JH. AMPA exposures induce mitochondrial Ca: 240-250.
18. Dugan LL, Sensi SL, Canzoniero LM, et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neu-rosci 1995; 15: 6377-6388.
19. Tymianski M, Charlton MP, Carlen PL, Tator CH. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 1993; 13: 2085-2104. (Pubitemid 23113418)
20. Sheen VL, Dreyer EB, Macklis JD. Calcium-mediated neuronal degeneration following singlet oxygen production. NeuroReport 1992; 3: 705-708.
21. Kakkar P, Mehrotra S, Viswanathan PN. Interrelation of active oxygen species, membrane damage and altered calcium functions. Molec Cell Biochem 1992; 111: 11-15.
22. Appel S, Alexianu M, Engelhardt J, et al. Involvement of immune factors in motor neuron cell injury in amyotrophic lateral sclerosis. In: Brown M, Meininger V, Swash M, eds. Amyotrophic Lateral Sclerosis © London: Martin Dunitz Ltd, 2000: 309-326.
23. Berger MM, Kopp N, Vital C, Redl B, Aymard M, Lina B. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000; 54: 20-25. (Pubitemid 30038732)
24. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochimica et Biophysica Acta 1991; 1083: 121-134.
25. Wang LH, Hajibeigi A, Xu XM, Loose-Mitchell D, Wu KK. Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem Biophys Res Comm 1993; 190: 406-411. (Pubitemid 23209625)
26. Smith CJ, Morrow JD, Roberts LJd, Marnett LJ. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide syn-thase-1 (COX-1). Biochem Biophys Res Comm 1993; 192: 787-793. (Pubitemid 23227391)
27. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iaco-belli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Experi Ther 1994; 271: 1705-1712. (Pubitemid 24382690)
28. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxyge-nase in biology and disease FASEB J 1998; 12: 1063-1073.
29. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-2510. (Pubitemid 24379628)
30. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of speciic cyclooxygenase-2 inhibitors. Arth Rheum 2000; 43: 4-13. (Pubitemid 30368207)
31. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24: 15-19.
32. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-1101.
33. Morita I, Schindler M, Regier MK, et al. Different intracellu-lar locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270: 10902-10908.
34. Smith WL, Dewitt DL. Prostaglandin endoperoxide H syn-thases-1 and -2. Ad Immunol 1996; 62: 167-215.
35. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interac-tions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318-4323. (Pubitemid 27194239)
36. Reddy ST, Herschman HR. Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells. J Biol Chem 1997; 272: 3231-3237. (Pubitemid 27066813)
37. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 296-315.
38. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93: 2317-2321. (Pubitemid 26104347)
39. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxyge-nase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-386. (Pubitemid 23250354)
40. Yaksh T. Central and peripheral mechanisms for the analgesic action of acetylsalicylic acid. In: Barrett H, Hirsh J, Mustard J, editors. Acetylsalicylic acid: New Uses for an Old Drug. New York: Raven Press; 1982: 137-151.
41. Coderre TJ, Gonzales R, Goldyne ME, West J, Levine JD. Noxious stimulus-induced increase in spinal prostaglandin E2 is noradrenergic terminal-dependent. Neurosci Lett 1990; 115: 253-258. (Pubitemid 20231623)
42. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996; 390: 165-169. (Pubitemid 26281193)
43. Beiche F, Klein T, Nusing R, Neuhuber W, Goppelt-Struebe M. Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord. J Neuroimmunol 1998; 89: 26-34. (Pubitemid 28389572)
44. Krowicki ZK, Nathan NA, Hornby PJ. Cyclooxygenase inhibition in the dorsal vagal complex of the rat evokes increases in gastric motor function. J Physiol, Paris 1997; 91: 209-213. (Pubitemid 27467026)
45. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterol 1997; 112: 387-397. (Pubitemid 27078825)
46. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98: 2076-2085. (Pubitemid 26376296)
47. Kopp UC, Cicha MZ, Smith LA, Haeggstrom JZ, Samuelsson B, Hokfelt T. Cyclooxygenase-2 involved in stimulation of renal mechanosensitive neurons. Hypertension 2000; 35: 373-378. (Pubitemid 30054202)
48. Inoue A, Ikoma K, Morioka N, et al. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J Neurochem 1999; 73: 2206-2213. (Pubitemid 29491836)
49. Beiche F, Brune K, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inlamm Res 1998; 47: 482-487. (Pubitemid 29015637)
50. Ichitani Y, Shi T, Haeggstrom JZ, Samuelsson B, Hokfelt T. Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inlammation: an in situ hybridization study. NeuroReport 1997; 8: 2949-2952. (Pubitemid 27394824)
51. Kaufmann WE, Worley PF, Taylor CV, Bremer M, Isakson PC. Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome. Brain Dev 1997; 19: 25- 34. (Pubitemid 27116980)
52. Chang JW, Coleman PD, O'Banion MK. Prostaglandin G/H synthase- 2(cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 1996; 17: 801-808. (Pubitemid 26348883)
53. Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deicient mice. A summary of their characteristics and susceptibilities to inlammation and carcinogenesis. Ann NY Acad Sci 1999; 889: 52-61. (Pubitemid 30040425)
54. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Experi Neurol 1997; 144: 339-349. (Pubitemid 27224561)
55. Kelley KA, Ho L, Winger D, et al. Potentiation of excitotoxi-city in transgenic mice overexpressing neuronal cyclooxyge-nase-2. Am J Pathol 1999; 155: 995-1004. (Pubitemid 29426846)
56. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997; 17: 2746-2755. (Pubitemid 27155008)
57. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML, Paetau A, Kaste M, Lindsberg PJ. Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 1998; 43: 738-747. (Pubitemid 28280217)
58. Tomimoto H, Akiguchi I, Wakita H, Lin JX, Budka H. Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta Neuropathol 2000; 99: 26-30. (Pubitemid 30093435)
59. Planas AM, Soriano MA, Justicia C, Rodriguez-Farre E. Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inlammation or neural cell damage. Neurosci Lett 1999; 275: 141-144. (Pubitemid 29502556)
60. Tonai T, Taketani Y, Ueda N, et al. Possible involvement of interleukin-1 in cyclooxygenase-2 induction after spinal cord injury in rats. J Neurochem 1999; 72: 302-309. (Pubitemid 29013905)
61. Dash PK, Mach SA, Moore AN. Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury. J Neurotrauma 2000; 17: 69-81. (Pubitemid 30075617)
62. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87: 319-324. (Pubitemid 28370892)
63. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hip-pocampal formation in Alzheimer's disease. J Neurosci Res 1999; 57: 295-303. (Pubitemid 29339785)
64. Oka A, Itoh M, Takashima S. The early induction of cyclooxygenase 2 associated with neuroibrillary degeneration in brains of patients with Fukuyama-type congenital muscular dystrophy. Neuropediatrics 1999; 30: 34-37. (Pubitemid 29161093)
65. Almer G, Vukosavic S, Romero N, Przedborski S. Upregulation of cyclo-oxygenase-2 in an animal model of familial amyotrophic lateral sclerosis. Neurology 2000; 54: A304.
66. Harris RE, Namboordiri KK, Farrar WB. Nonsteroidal anti-inlammatory drugs and breast cancer. Epidemiol 1996; 7: 203-205. (Pubitemid 26068056)
67. Smalley W, Ray WA, Daugherty J, Grifin MR. Use of nons-teroidal anti-inlammatory drugs and incidence of colorec-tal cancer: a population-based study. Arch Intern Med 1999; 159: 161-166. (Pubitemid 29055104)
68. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996; 56: 733-737. (Pubitemid 26060513)
69. Patrignani P. Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. Toxicol Lett 2000; 112-113: 493-498. (Pubitemid 30138208)
70. Dubois RN. Review article: cyclooxygenase-a target for colon cancer prevention. Alimentary Pharmacol Ther 2000; 14: 64-67. (Pubitemid 30199107)
71. Smalley WE, DuBois RN. Colorectal cancer and nons-teroidal anti-inlammatory drugs. Advances in Pharmacol (New York) 1997; 39: 1-20.
72. Buckman SY, Gresham A, Hale P, et al. COX-2 expression in induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-729. (Pubitemid 28376760)
73. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxy-genase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatol 1999; 29: 688-696. (Pubitemid 29109581)
74. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001. (Pubitemid 28521147)
75. Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 1998; 13: 591-597. (Pubitemid 28197721)
76. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21. (Pubitemid 30078300)
77. Battu S, Rigaud M, Beneytout JL. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarci-noma cell line HT29 CL.19A. Anti cancer Res 1998; 18: 3579-3583. (Pubitemid 28546493)
78. Subbaramaiah K, Telang N, Bansal MB, Weksler BB, Dannenberg AJ. Cyclooxygenase-2 gene expression is upregu-lated in transformed mammary epithelial cells. Ann NY Acad Sci 1997; 833: 179-185. (Pubitemid 28045253)
79. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum appears in Cell 1998; 94: following 271]. Cell 1998; 93: 705-716. (Pubitemid 28257578)
80. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Nat Acad Sci USA 1997; 94: 657-662. (Pubitemid 27053689)
81. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inlammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3: 1679-1683. (Pubitemid 27444704)
82. Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999; 81: 101-107. (Pubitemid 29393786)
83. Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Japan J Cancer Res 1997; 88: 600-604. (Pubitemid 27348497)
84. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
85. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 1997; 17(1A): 337-342. (Pubitemid 27116689)
86. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Nat Acad Sci USA 1997; 94: 3336-3340. (Pubitemid 27157312)
87. Resnick DK, Graham SH, Dixon CE, Marion DW. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma 1998; 15: 1005-1013. (Pubitemid 28560043)
88. Ho L, Osaka H, Aisen PS, Pasinetti GM. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol 1998; 89: 142-149. (Pubitemid 28389586)
89. Akaike A, Kaneko S, Tamura Y, et al. Prostaglandin E2 protects cultured cortical neurons against N-methyl-D-aspar- tate receptor-mediated glutamate cytotoxicity. Brain Research 1994; 663: 237-243.
90. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999; 843: 118-129. (Pubitemid 29488702)
91. Miyamoto K, Oka N, Kawasaki T, Satoi H, Matsuo A, Akiguchi I. The action mechanism of cyclooxygenase-2 inhibitor for treatment of experimental allergic neuritis. Muscle Nerve 1999; 22: 1704-1709.
92. Sasaki S, Iwata M. Ultrastructural change of synapses of Betz cells in patients with amyotrophic lateral sclerosis. Neurosci Lett 1999; 268: 29-32. (Pubitemid 29292537)
93. Engelhardt JI, Siklos L, Komuves L, Smith RG, Appel SH. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 1995; 20: 185-199.
94. Gonatas NK, Gonatas JO, Stieber A. The involvement of the Golgi apparatus in the pathogenesis of amyotrophic lateral sclerosis, Alzheimer's disease, and ricin intoxication. His-tochem Cell Biol 1998; 109: 591-600. (Pubitemid 28289232)
95. Appel SH, Engelhardt JI, Garcia J, Stefani E. Immunoglobu-lins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc Nat Acad Sci USA 1991; 88: 647-651. (Pubitemid 21915523)
96. O'Shaughnessy TJ, Yan H, Kim J, et al. Amyotrophic lateral sclerosis: serum factors enhance spontaneous and evoked transmitter release at the neuromuscular junction. Muscle Nerve 1998; 21: 81-90. (Pubitemid 28041684)
97. Mosier DR, Siklos L, Appel SH. Resistance of extraocular motoneuron terminals to effects of amyotrophic lateral sclerosis sera. Neurology 2000; 54(Pt 1): 252-255. (Pubitemid 30038776)
98. Andjus PR, Stevic-Marinkovic Z, Cherubini E. Immunoglobulins from motoneurone disease patients enhance glutamate release from rat hippocampal neurones in culture. J Physiol 1997; 504: 103-112. (Pubitemid 27464277)
99. Llinas R, Sugimori M, Cherksey BD, et al. IgG from amy-otrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer. Proc Nat Acad Sci USA 1993; 90: 11743-11747. (Pubitemid 24008715)
100. Bernstein LP, Antel JP. Motor neuron disease: decremental responses to repetitive nerve stimulation. Neurology 1981; 31: 204-207. (Pubitemid 11137606)
101. Denys E, Norris F. Amyotrophic Lateral Sclerosis: impairment of neurologic transmission. Arch Neurol 1957; 36: 202-205.
102. Killian JM, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve 1994; 17: 747-754. (Pubitemid 24191491)
103. Mulder D, Lambert E, Eaton L. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 1959; 9: 627-631.
104. Stalberg E. Electrophysiological studies of reinnervation in ALS. Adv Neurol 1982; 36: 47-59.
105. Maselli RA, Wollman RL, Leung C, et al. Neuromuscular transmission in amyotrophic lateral sclerosis. Muscle Nerve 1993; 16: 1193-1203. (Pubitemid 23304857)
106. Smith RG, Kimura F, Harati Y, McKinley K, Stefani E, Appel SH. Altered muscle calcium channel binding kinetics in autoimmune motoneuron disease. Muscle Nerve 1995; 18: 620-627.
107. Sharma KR, Miller RG. Electrical and mechanical properties of skeletal muscle underlying increased fatigue in patients with amyotrophic lateral sclerosis. Muscle Nerve 1996; 19: 1391-1400. (Pubitemid 26349495)
108. Kelemen J, Hedlund W, Orlin JB, Berkman EM, Munsat TL. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch Neurol 1983; 40: 752-753. (Pubitemid 14230514)
109. Monstad I, Dale I, Petlund CF, Sjaastad O. Plasma exchange in motor neuron disease. A controlled study. J Neurol 1979; 221: 59-66. (Pubitemid 9245039)
110. Olarte MR, Schoenfeldt RS, McKiernan G, Rowland LP. Plasmapheresis in amyotrophic lateral sclerosis. Ann Neurol 1980; 8: 644-645.
111. Norris FH, Jr., Denys EH, Mielke CH, Jr. Plasmapheresis (plasma exchange) in neurologic disorders. Clin Neu-ropharmacol 1982; 5: 93-114. (Pubitemid 12023909)
112. Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S. Effect of high-dose intravenous immunoglob-ulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 1994; 51: 861-864. (Pubitemid 24286040)
113. Euler HH, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. Ann Med Intern 1994; 145: 296-302. (Pubitemid 24349872)
114. Illei GG, Klippel JH. Novel approaches in the treatment of lupus nephritis. Lupus 1998; 7: 644-648. (Pubitemid 29008233)
115. Kovacs B, Lafferty T, Brent L, DeHoratius R. Transverse myelopathy in systemic lupus erythematosis: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59: 120-124. (Pubitemid 30305609)
116. Sheil R, Bambauer R, Latza R, Klinkmann J. Cyclosporin and plasmapheresis in treatment of progressive systemic lupus erythematosis. Transfus Sci 1997; 18: 91-97.
117. Wallace DJ. Apheresis for lupus erythematosus. Lupus 1999; 8: 174-180. (Pubitemid 29186835)
118. Merkel F, Netzer KO, Gross O, Marx M, Weber M. Therapeutic options for critically ill patients suffering from progressive lupus nephritis or Goodpasture's syndrome. Kidney 1998; 64(Suppl): S31-S38. (Pubitemid 28096463)
119. Yeh JH, Chiu HC. Sequential plasmapheresis and intravenous immunoglobulin therapy for refractory myasthenia gravis: case report. Thera Apheresis 1999; 3: 271-274.
120. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheum 1991; 18: 270-276.
121. Smith R, Gooch C, Werch J, Armstrong R, Killian J. Effect of plasmapheresis and intravenous immune globulin on neu-romuscular junction function in sporadic ALS patients. Neurology 1998; 50: a416-417.
122. Mosier D, Werch J, Appel S, Smith R. Neuromuscular effects of plasmapheresis fractions from patients with sporadic amyotrophic lateral sclerosis. Neurology 1998; 50: a416.